← SynDRA
BEPOTASTINE
SynDRA canonical compound SYN0023606 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | HRH1 |
|---|
| Mechanism of action | Histamine receptor antagonist |
|---|
| Indication | conjunctivitis |
|---|
| Disease area | ophthalmology |
|---|
All known targets
Mechanisms of action (all sources)
- Histamine receptor antagonist
- HRH1 ANTAGONIST
- Histamine H1 receptor antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ACHE
- HTR2B
- SLC6A4
- SLC6A3
- SLC6A2
- PTGS1
- PGR
- PDE4A
- PDE3A
- OPRM1
- MAOA
- KDR
- KCNH2
- HTR1A
- ADORA3
- HRH3
- HDAC6
- F2
- ESR1
- DRD3
- DRD1
- CHRM2
- CHRM1
- AR
- ADRA2A
- ADRA1A
- TBXA2R
Drug classes
- Histamine-1 Receptor Antagonist
- Anti-Allergic Agents
Cross-references
Synonyms
- BEPOTASTINE BESILATE
- BEPREVE
- Bepreve
- bepotastine besilate
- bepreve
- bepotastine besylate
- Bepotastina
- Betotastine
- Tau 284
- TAU-284DS
- Talion (TN)
- HYD2U48IAS
- bepotastina
- tau-284
- bepotastinum
- CHEBI:71204
- RefChem:56382
- DTXCID201334062
- Bepotastine >90%
- MFCD06798155
- Bepotastine [INN]
- UNII-HYD2U48IAS
- Bepotastine [USAN:INN]
- BEPOTASTINE [MI]
- Bepotastine (USAN/INN)
- BEPOTASTINE [USAN]
- BEPOTASTINE [VANDF]
- BEPOTASTINE [MART.]
- SCHEMBL29459
- BEPOTASTINE [WHO-DD]
- GTPL7466
- orb1299407
- orb3025862
- SCHEMBL29440897
- TQP0323
- GLXC-07023
- CS-M1828
- CS-M1895
Reported adverse events
Look up BEPOTASTINE in the interactive SynDRA portal →